×

Warning

Joomla\CMS\Cache\Storage\FileStorage::_deleteFolder Failed deleting 6757425499eac20291c301b132bc46c6-cache-mod_menu-bb92200784df98fe8af389c7dd893526.php

medimmune-iain-chessell

MedImmune in Cambridge UK is reaching out to academics and biotech companies in a bid to improve the industry’s poor neuroscience track record.

Together with AstraZeneca in Boston, Massachusetts, MedImmune – the global biologics unit of AstraZeneca – is setting up a collaborative unit at its Granta Park HQ with the aim of producing drugs to treat neurodegenerative conditions, long term pain and neuropsychiatric conditions.

Iain Chessell, vice-president R & D Neuroscience said: “There have been no new approvals of completely novel mechanisms for treating pain for at least a decade – if not more – and current treatment only works in a third to half of patients.